Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | CTSK | P43235 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 4/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MGAM | O43451 | 1/20 | 0.44 |
| ▸ | SI | P14410 | 1/20 | 0.44 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 2/20 | 0.42 |
| ▸ | CA1 | P00915 | 2/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | CA9 | Q16790 | 2/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1784924 | 0.88 | CTSK (0.51) | TDP1CTSKGAAMEN1KMT2A | |
| SCHEMBL25827367 | 0.86 | GAA (0.58) | TDP1CTSKGAAMEN1KMT2A | |
| SCHEMBL15728746 | 0.86 | CTSK (0.50) | TDP1CTSKGAAMEN1KMT2A | |
| SCHEMBL3193384 | 0.85 | TDP1 (0.50) | TDP1GAAMEN1KMT2AHTT | |
| SCHEMBL1695195 | 0.83 | MEN1 (0.48) | TDP1CTSKGAAMEN1KMT2A | |
| SCHEMBL572949 | 0.82 | TDP1 (0.56) | TDP1CTSKGAAMEN1KMT2A | |
| SCHEMBL14038535 | 0.81 | TDP1 (0.53) | TDP1GAAMEN1KMT2AHTT | |
| SCHEMBL25095054 | 0.81 | TDP1 (0.58) | TDP1CTSKGAAMEN1KMT2A | |
| SCHEMBL6433337 | 0.80 | TDP1 (0.43) | TDP1CTSKGAAMEN1KMT2A | |
| SCHEMBL5397743 | 0.80 | GAA (0.53) | TDP1GAAMEN1KMT2AHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11718588-B2 | 5-[(piperazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS inhibitors for the treatment of osteoarthritis | GALAPAGOS NV (BE) | 2023-08-08 | — | — | US | disclosed |
| US-11718588-B2 | 5-[(piperazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS inhibitors for the treatment of osteoarthritis | GALAPAGOS NV (BE) | 2023-08-08 | — | — | US | disclosed |
| US-11718588-B2 | 5-[(piperazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS inhibitors for the treatment of osteoarthritis | GALAPAGOS NV (BE) | 2023-08-08 | — | — | US | disclosed |
| US-20210309614-A1 | 5-[(PIPERAZIN-1-YL)-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS ADAMTS INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS | GALAPAGOS NV (BE) | 2021-10-07 | — | — | US | disclosed |
| US-20210309614-A1 | 5-[(PIPERAZIN-1-YL)-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS ADAMTS INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS | GALAPAGOS NV (BE) | 2021-10-07 | — | — | US | disclosed |
| US-10941117-B2 | 5-[(piperazin-l-yl)-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS inhibitors for the treatment of osteoarthritis | GALAPAGOS NV (BE) | 2021-03-09 | — | — | US | disclosed |
| US-20200216397-A1 | 5-[(PIPERAZIN-1-YL)-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS ADAMTS INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS | GALAPAGOS NV (BE) | 2020-07-09 | — | — | US | disclosed |
| CN-107108579-B | Imidazolidine-2, 4-dione derivatives as ADAMTS inhibitors for the treatment of osteoarthritis | 加拉帕戈斯股份有限公司 | 2019-12-17 | — | — | CN | disclosed |
| EP-3575294-A1 | 5-[(PIPERAZIN-1-YL)-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS ADAMTS INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS | Les Laboratoires Servier (FR) | 2019-12-04 | — | — | EP | disclosed |
| EP-3575294-A1 | 5-[(PIPERAZIN-1-YL)-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS ADAMTS INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS | Les Laboratoires Servier (FR) | 2019-12-04 | — | — | EP | disclosed |
| EP-1660085-B1 | PYRIDYLPYRROLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | PFIZER ITALIA SRL (IT) | 2008-10-15 | — | — | EP | disclosed |
| EP-1973910-A1 | PYRROLO Ý3,2-C¨PYRIDINE-4-ONE 2-INDOLINONE PROTEIN KINASE INHIBITORS | Shanghai Hengrui Pharmaceutical Co. Ltd. (CN) | 2008-10-01 | — | — | EP | disclosed |
| WO-2007085188-A1 | PYRROLO [3,2-C] PYRIDINE-4-ONE 2-INDOLINONE PROTEIN KINASE INHIBITORS | SHANGHAI HENGRUI PHARMACEUTICAL CO. LTD. (CN) | 2007-08-02 | — | — | WO | disclosed |
| WO-2007068728-A2 | N-SUBSTITUTED PYRROLOPYRIDINONES ACTIVE AS KINASE INHIBITORS | PFIZER ITALIA SRL (IT) | 2007-06-21 | — | — | WO | disclosed |
| US-20070142414-A1 | N-substituted pyrrolopyridinones active as kinase inhibitors | PHARMACIA ITALIA S.P.A. (IT) | 2007-06-21 | — | — | US | disclosed |
| EP-1705175-A1 | Process for preparing C5 products and their use for Atorvastatin synthesis | ratiopharm GmbH (DE) | 2006-09-27 | — | — | EP | disclosed |
| EP-1660085-A1 | PYRIDYLPYRROLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | Pharmacia Italia S.p.A. (IT) | 2006-05-31 | — | — | EP | disclosed |
| US-20050043346-A1 | Pyridylpyrrole derivatives active as kinase inhibitors | PHARMACIA ITALIA S.P.A. (IT) | 2005-02-24 | — | — | US | disclosed |
| WO-2005013986-A1 | PYRIDYLPYRROLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | PHARMACIA ITALIA S.P.A. (IT) | 2005-02-17 | — | — | WO | disclosed |
| US-5599954-A | N-substituted-7-amino-5-hydroxy-3-oxoheptanoic acid derivatives and method for producing the same | TAKASAGO INTERNATIONAL CORPORATION (JP) | 1997-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043346-A1 | Pyridylpyrrole derivatives active as kinase inhibitors | MAP3K6, MAP3K5, MAP4K2 | TDP1 1002/4885CTSK 2454/4885GAA 1253/4885 |
| US-20200216397-A1 | 5-[(PIPERAZIN-1-YL)-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS ADAMTS INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS | ADAMTS1, ADAMTS5, ADAMTS7 | TDP1 945/4885CTSK 181/4885GAA 3266/4885 |
| US-20210309614-A1 | 5-[(PIPERAZIN-1-YL)-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS ADAMTS INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS | ADAMTS1, ADAMTS5, ADAMTS7 | TDP1 945/4885CTSK 181/4885GAA 3266/4885 |
| US-11718588-B2 | 5-[(piperazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS inhibitors for the treatment of osteoarthritis | ADAMTS1, ADAMTS5, ADAMTS7 | TDP1 945/4885CTSK 181/4885GAA 3266/4885 |
| US-20070142414-A1 | N-substituted pyrrolopyridinones active as kinase inhibitors | CDK2, MAP3K19, MAP3K7 | TDP1 840/4885CTSK 1306/4885GAA 3382/4885 |
| US-10941117-B2 | 5-[(piperazin-l-yl)-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS inhibitors for the treatment of osteoarthritis | ADAMTS5, ADAMTS1, ADAMTS7 | TDP1 1144/4885CTSK 164/4885GAA 3061/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.